Clinical Trials: Clinical Trials in USA

The Role of FDA Type A, B, and C Meetings in U.S. Clinical Programs

Posted on digi By digi

Sponsors should: (1) submit detailed meeting packages; (2) craft focused regulatory questions; (3) prepare multidisciplinary teams; (4) align internal decision-making before meetings; (5) document FDA responses carefully; (6) engage regulatory experts; (7) consider mock rehearsals; (8) maintain respectful and collaborative interactions; (9) follow up promptly with meeting minutes; and (10) integrate FDA advice into global strategy.

Click to read the full article.

Clinical Trials in USA, Country-Specific Clinical Trials

FDA Approach to Digital Endpoints in U.S. Clinical Trials

Posted on digi By digi

Sponsors should: (1) validate digital tools thoroughly; (2) engage FDA early to discuss digital endpoint proposals; (3) ensure data integrity and cybersecurity compliance; (4) incorporate patient feedback in endpoint selection; (5) establish SOPs for device use and troubleshooting; (6) monitor patient adherence; (7) conduct pilot studies before pivotal trials; (8) document all validation studies; (9) align SAPs with digital endpoints; and (10) maintain inspection-ready data systems.

Click to read the full article.

Clinical Trials in USA, Country-Specific Clinical Trials

Multicenter Academic Clinical Trials in the United States: Regulatory and Operational Perspectives

Posted on digi By digi

Sponsors and investigators should: (1) establish centralized IRB review; (2) implement harmonized SOPs across sites; (3) invest in electronic data management systems; (4) apply risk-based monitoring; (5) train all staff in GCP; (6) plan realistic recruitment strategies; (7) engage patient advocacy groups; (8) foster collaboration across institutions; (9) secure sustainable funding; and (10) maintain inspection readiness across all participating sites.

Click to read the full article.

Clinical Trials in USA, Country-Specific Clinical Trials

FDA Inspections of Phase 1 Clinical Units in the United States

Posted on digi By digi

Sponsors and Phase 1 units should: (1) maintain thorough informed consent processes; (2) ensure real-time safety monitoring; (3) validate EDC systems for Part 11 compliance; (4) maintain meticulous IP accountability; (5) conduct routine staff training; (6) audit CROs and vendors; (7) implement SOPs for protocol deviations; (8) conduct internal audits; (9) prepare inspection readiness binders; and (10) establish corrective and preventive action (CAPA) programs for identified deficiencies.

Click to read the full article.

Clinical Trials in USA, Country-Specific Clinical Trials

FDA Clinical Data Submission Standards: CDISC and U.S. Trial Requirements

Posted on digi By digi

Sponsors should: (1) adopt CDISC standards early in trial design; (2) validate datasets with Pinnacle 21 before submission; (3) maintain traceability from raw data to analysis outputs; (4) ensure Define.xml completeness; (5) harmonize terminology across studies; (6) train staff in CDISC standards; (7) audit CRO deliverables; (8) integrate SEND into nonclinical workflows; (9) establish SOPs for data standardization; and (10) maintain documentation for FDA inspections.

Click to read the full article.

Clinical Trials in USA, Country-Specific Clinical Trials

IND Maintenance During Ongoing Clinical Trials in the United States

Posted on digi By digi

Sponsors should: (1) establish SOPs for IND maintenance; (2) implement electronic systems for submission tracking; (3) perform regular compliance audits; (4) maintain updated investigator lists; (5) monitor safety signals continuously; (6) ensure consistency between IND and global submissions; (7) engage CROs with robust regulatory experience; (8) conduct staff training on IND obligations; (9) prepare inspection-ready records; and (10) document CAPA for identified deficiencies.

Click to read the full article.

Clinical Trials in USA, Country-Specific Clinical Trials

Expanded Role of Wearables in U.S. Clinical Trials

Posted on digi By digi

Sponsors should: (1) validate devices rigorously; (2) engage FDA early regarding wearable endpoints; (3) ensure interoperability and cybersecurity; (4) establish SOPs for device use; (5) train patients effectively; (6) monitor adherence remotely; (7) implement quality assurance programs for wearable data; (8) conduct pilot studies before pivotal trials; (9) engage with patient advocacy groups; and (10) prepare inspection-ready documentation of wearable integration.

Click to read the full article.

Clinical Trials in USA, Country-Specific Clinical Trials

FDA Guidance on Informed Consent in Digital Settings

Posted on digi By digi

Sponsors should: (1) implement Part 11-compliant systems; (2) test comprehension with participants; (3) train investigators and coordinators in eConsent use; (4) provide multilingual content; (5) ensure HIPAA compliance; (6) establish audit trails; (7) integrate eConsent into clinical trial workflows; (8) validate technology prior to deployment; (9) monitor ongoing compliance; and (10) involve IRBs early in design and implementation.

Click to read the full article.

Clinical Trials in USA, Country-Specific Clinical Trials

Post-Approval Commitments and Phase 4 Clinical Trials in the U.S.

Posted on digi By digi

Sponsors should: (1) establish dedicated teams for post-approval commitments; (2) maintain proactive communication with FDA; (3) integrate RWE sources with traditional trial data; (4) conduct feasibility assessments for long-term follow-up; (5) align global post-marketing requirements with FDA obligations; (6) track commitments with compliance dashboards; (7) engage CROs with long-term study expertise; (8) involve patient advocacy groups; (9) maintain inspection readiness; and (10) implement CAPA systems for delays or deficiencies.

Click to read the full article.

Clinical Trials in USA, Country-Specific Clinical Trials